However, even without concomitant SV2A drug intake, the efficacy of PSL was modest, and 75% responder rates were not better than those observed in pivotal trials with other ASMs in populations of comparable epilepsy severity.16, 17, 18, 19. This evidence concerns the gene SV2A and epilepsy.